XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
OPERATING CASH FLOW      
Net earnings (loss) $ 73 $ (401) $ (367)
Adjustments to reconcile net earnings (loss) to operating cash flow:      
Impairment expense - Cont Ops (24) 290 298
Impairment expense - Disc Ops 0 0 146
(Gain) loss on pension settlement (42) 198 0
Depreciation and amortization 73 74 105
(Earnings) loss from equity method investments, net of distributions (15) (8) (4)
(Gain) loss on sales of assets incl. AMECO-North America (35) (2) (1)
(Gain) loss on debt repurchases 0 20 0
Stock-based compensation 19 32 22
Deferred taxes 17 28 (20)
Net contributions to employee pension plans (2) (12) (21)
Changes in assets and liabilities (46) (197) 31
Other 13 3 (3)
Operating cash flow 31 25 186
INVESTING CASH FLOW      
Purchases of marketable securities (428) (149) (35)
Proceeds from sales and maturities of marketable securities 364 45 19
Capital expenditures (75) (75) (113)
Proceeds from sales of assets incl. AMECO-North America 95 146 112
Investments in partnerships and joint ventures (53) (80) (29)
Other 19 (9) 5
Investing cash flow (78) (122) (41)
FINANCING CASH FLOW      
Proceeds from NuScale de-SPAC transaction 341 0 0
Proceeds from sale of NuScale interest 107 0 0
Proceeds from issuance of CPS 0 582 0
Purchases and retirement of debt (41) (525) 0
Debt extinguishment costs 0 (2) 0
Dividends paid (on CPS in 2022 and 2021 and common stock in 2020) (39) (19) (29)
Other borrowings (debt repayments) (4) (6) 4
Distributions paid to NCI (60) (109) (23)
Capital contributions by NCI 21 202 110
Other (10) (1) (14)
Financing cash flow 315 122 48
Effect of exchange rate changes on cash (38) (15) 9
Increase (decrease) in cash and cash equivalents 230 10 202
Cash and cash equivalents at beginning of year 2,209 2,199 1,997
Cash and cash equivalents at end of year $ 2,439 $ 2,209 $ 2,199